Obesity treatment: novel peripheral targets.
Our knowledge of the complex mechanisms underlying energy homeostasis has expanded enormously in recent years. Food intake and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including cholecystokinin, glucagon-like peptide-1, peptide YY, oxyntomodulin, amylin, pancreatic polypeptide and ghrelin, have been shown to play an important role in regulating short-term food intake. These hormones therefore represent potential targets in the development of novel anti-obesity drugs. This review focuses on the role of gut hormones in short- and long-term regulation of food intake, and on the current state of development of gut hormone-based obesity therapies.
Field
Benjamin C T
BC
Department of Investigative Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK.
Chaudhri
Owais B
OB
Bloom
Stephen R
SR
D000682:Amyloid / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001067:Appetite Depressants / Q000627:therapeutic use*; D001069:Appetite Regulation / Q000187:drug effects*; D002766:Cholecystokinin / Q000627:therapeutic use; D004435:Eating / Q000502:physiology; D004734:Energy Metabolism / Q000502:physiology; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D054439:Ghrelin / Q000627:therapeutic use; D006801:Humans; D058228:Islet Amyloid Polypeptide; D009765:Obesity / Q000188:drug therapy*; D053772:Oxyntomodulin / Q000627:therapeutic use; D010191:Pancreatic Polypeptide / Q000627:therapeutic use; D019894:Peptide YY / Q000627:therapeutic use
D000682:Amyloid; D019440:Anti-Obesity Agents; D001067:Appetite Depressants; D005765:Gastrointestinal Agents; D054439:Ghrelin; D058228:Islet Amyloid Polypeptide; D053772:Oxyntomodulin; D019894:Peptide YY; D010191:Pancreatic Polypeptide; D002766:Cholecystokinin